1416440-14-6

Basic information

• Product Name: methyl 4-chloroquinoline-8-carboxylate
• Synonyms: methyl 4-chloroquinoline-8-carboxylate;4-Chloro-quinoline-8-carboxylic acid methyl ester
• CAS NO: 1416440-14-6
• Molecular Formula: C11H8ClNO2
• Molecular Weight: 221.63972
• Mol File: 1416440-14-6.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 333.6±22.0 °C(Predicted)
• Appearance: /
• Density: 1.330±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 1.75±0.30(Predicted)
• CAS DataBase Reference: methyl 4-chloroquinoline-8-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-chloroquinoline-8-carboxylate(1416440-14-6)
• EPA Substance Registry System: methyl 4-chloroquinoline-8-carboxylate(1416440-14-6)

Safety Data

• Hazardous Substances Data: 1416440-14-6(Hazardous Substances Data)

Usage

General Description

Methyl 4-chloroquinoline-8-carboxylate is a chemical compound that belongs to the class of quinoline derivatives. It is a methyl ester of 4-chloroquinoline-8-carboxylic acid, featuring a methyl group and a chlorine atom attached to the quinoline nucleus. methyl 4-chloroquinoline-8-carboxylate has potential applications in pharmaceutical and agrochemical industries, as it can serve as an intermediate in the synthesis of various bioactive molecules and pesticides. Additionally, it exhibits interesting pharmacological properties, making it a subject of interest in medicinal chemistry research. Overall, methyl 4-chloroquinoline-8-carboxylate is a versatile chemical with diverse potential uses in various fields.

Upstream product

• 386207-63-2 4-hydroxyquinoline-8-carboxylic acid 
• 860206-84-4 methyl 4-hydroxyquinoline-8-carboxylate 
• 185130-13-6 methyl 2-(((2,2-dimethyl-4,6-dioxo-1 ,3-dioxan-5-ylidene)methyl)amino)benzoate 
• 134-20-3 2-carbomethoxyaniline 

Relevant articles and documents

TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS.

The present invention relates to compounds of general formula (I), tautomers, stereoisomers, N-oxides, pharmaceutically acceptable salts and pro-drug thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy: wherein: a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -N(R)2, and -SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); a C3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); Y represents: an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); a 5- or 6-membered, saturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or a C3-6 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); and Z represents: an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -OH, -N(R' )2 (where each R1 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2R2 (where R2 is H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2N(R3)2 (where each R3 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), and -C(0)N(R4)2 (where each R4 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl, or wherein both R4 groups, together with the intervening nitrogen atom, form a 3 to 6 membered saturated heterocyclic ring); or an unsaturated, 5- to 10-membered mono- or bicyclic heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -OH, -N(R')2 (where each R1 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2R2 (where R2 is H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2N(R3)2 (where each R3 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), and -C(O)N(R4)2 (where each R4 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl, or wherein both R4 groups, together with the intervening nitrogen atom, form a 3 to 6 membered saturated heterocyclic ring); with the proviso: that when the compound is other than an N-oxide of formula (I), Z must be substituted by at least one substituent selected from -OH, -N(R3)2, -SO2N(R3)2 and -C(O)N(R4)2, preferably by at least one substituent selected from -OH, -SO2N(R3)2 and -C(O)N(R4)2. These compounds find particular use in the treatment and/or prevention of a disease or disorder responsive to inhibition of tankyrase 1 and/or 2, for example a disorder which is mediated by tankyrase 1 and/or 2 such as cancer.